Frovocimab Reference: HY-P99626 Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
Urelumab Reference: HY-P99055 Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
Ascrinvacumab Reference: HY-P99353 Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC).
Telazorlimab Reference: HY-P99570 Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases.
Tremelimumab Reference: HY-P9918 Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
Adalimumab (anti-TNF-α) Reference: HY-P9908A Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
Labetuzumab Reference: HY-P99160 Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.
Iscalimab Reference: HY-P99670 Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.
Lerdelimumab Reference: HY-P99695 Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
Ziltivekimab Reference: HY-P99505 Ziltivekimab (COR-001) is a human anti-IL-6 monoclonal antibody that is effective in reducing serum CRP. Ziltivekimab has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD.
Pivekimab Reference: HY-P99234 Pivekimab is a human IgG1 monoclonal antibody targeting interleukin 3 (IL-3) and CD123. Pivekimab can be used in the study of blastocytic plasmacytoid dendritic cell tumor (BPDCN).
Grisnilimab setaritox Reference: HY-P99651 Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID50 of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys.